A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Investigator: Polly Niravath, MD

Study Coordinator: Kelsey Banaglorioso

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT03199885

Phone: 346.238.5740

Protocol Number: PRO00024928


This randomized phase III trial studies how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
More to Explore